SMO or PTCH-1 (Hedgehog)

1 regimens on this page 1 variants on this page

All lines of therapy

Vismodegib monotherapy

Regimen

Study	Dates of enrollment	Evidence
Hainsworth et al. 2018 (MyPathway)	2014-2016	Phase 2a

Biomarker eligibility criteria

• SMO p.W535L or other nonsynonymous mutations, or PTCH-1 loss-of-function mutations

Targeted therapy

• Vismodegib (Erivedge) 150 mg PO once per day

Continued indefinitely

References

1. MyPathway: Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018 Feb 20;36(6):536-542. Epub 2018 Jan 10. link to original article contains dosing details in manuscript PubMed https://clinicaltrials.gov/ct2/show/NCT02091141